David MacDonald

EUSA Pharma, a biopharmaceutical company focused on oncology and rare disease, in its acquisition (pending HSR review) of the global rights to SYLVANT® (siltuximab) for $115 million from Janssen Sciences Ireland UC, a subsidiary of Janssen R&D Ireland. SYLVANT® is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition.

Tigen Pharma SA in an option and collaboration agreement with the Ludwig Institute for Cancer Research for exclusive option rights to breakthrough and proprietary technologies for T-cell based cancer immunotherapy developed in the Lausanne Branch of LICR in collaboration with the University of Lausanne and Centre Hospitalier Universitaire Vaudois.

Spectrum Brands in its $2 billion carve-out sale of its global consumer battery business to Energizer.

Teva Pharmaceutical Industries, Ltd. in its exclusive licensing agreement with Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab (TEV-48125), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine, in Japan.

Sun Pharmaceutical Industries Ltd in its acquisition of the anti-cancer agent sonidegib (LDE225), a Hedgehog signaling pathway inhibitor, marketed as Odomzo, from Novartis, for an upfront payment of $175 million and additional milestone payments.

Welsh, Carson, Anderson & Stowe in its carve-out acquisition of QuickBase, Inc. from Intuit, Inc.

Sun Pharmaceutical Industries Ltd. in its licensing agreement with Almirall for the development and commercialization of tildrakizumab (MK-3222) biologic for chronic plaque psoriasis in Europe.

Teva Pharmaceutical Industries Ltd. in its agreement with Takeda Pharmaceutical Company Limited to form a new business venture to offer patients and the healthcare system in Japan the portfolio of Teva’s high-quality generic medicines and Takeda’s long listed products.

Purdue Pharma in its worldwide collaboration agreement with Eisai Inc. to develop and commercialize Eisai’s clinical candidate lemborexant, a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia.

Bristol-Myers Squibb in the restructuring of its Erbitux ® (cetuximab) collaboration in North America with Eli Lilly, transferring rights to the product in North America from Bristol-Myers Squibb to Lilly, including full commercialization and manufacturing operational responsibilities.

Sun Pharmaceutical Industries in its agreement with Sharp & Dohme Corp. for the development, manufacture and commercialization of Merck’s tildrakizumab (MK-3222) biologic worldwide for chronic plaque psoriasis.

Pfizer Inc. in connection with its $635 million acquisition of the marketed vaccines portfolio of Baxter International Inc.

Bristol-Myers Squibb Company in connection with the $4.3 billion sale of its global diabetes business to its collaboration partner AstraZeneca.

Nordex Energy GmbH in licensing patents related to zero voltage ride through technology for wind energy turbines from GE Infrastructure Technology LLC.

DuPont Pioneer in licensing agreements with Monsanto Company for next-generation soybean technologies in the United States and Canada, regulatory data rights and access to disease resistance and corn defoliation patents.

Pfizer Inc. in its agreement to acquire from AstraZeneca the over-the-counter rights worldwide for NEXIUM, a prescription drug for treatment of the symptoms of gastroesophageal reflux disease.

Sun Pharmaceutical Industries in forming a joint venture with Merck & Co., Inc. to bring innovative and differentiated drug formulations to emerging markets in a global development, licensing, supply, sales and marketing collaboration.

Bristol-Myers Squibb Company in its $885 million acquisition of ZymoGenetics, a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases.

Danaher Corporation in its $1.1 billion acquisition of the AB Sciex mass spectrometry business, and Molecular Devices Corporation, an analytical instrumentation company from Life Technologies Corp. and MDS, Inc.

Lucent Technologies as part of Kirkland team in forming the Multimedia Patent Trust for patent infringement suit where Lucent and MPT asserted patents related to various software and hardware applications.

Samsung Electronics Co. Ltd. in financing of Picsel (Research) Limited and Picsel Technologies, while Picsel was in UK administration proceedings, in exchange for rights in patents and other intellectual property.

Associate, Skadden, Arps, Slate, Meagher & Flom LLP, 1997–1999